We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » Pharmaceuticals » Submissions and Approvals

Submissions and Approvals
Submissions and Approvals RSS Feed RSS

Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

June 30, 2022
Gilead is seeking approval of lenacapavir for treatment of HIV-1 infection in heavily treatment-experienced individuals with multi-drug resistant HIV-1 infection. Read More

EU Expands Approval of Novartis’ Cosentyx for Pediatric Arthritis

June 29, 2022
Cosentyx, a human interleukin-17A antagonist, is also FDA-approved. Read More

CHMP Recommends Nine New Drugs in Latest Monthly Meeting

June 27, 2022
The European Medicines Agency (EMA)’s human medicines committee endorsed nine new drugs during its June meeting, including Valneva’s adjuvanted COVID-19 vaccine for use in people age 18 to 50 years. Read More

Novartis’ Tabrecta Gained EU Approval for Advanced NSCLC

June 24, 2022
In May 2020, the oral kinase inhibitor received accelerated approval from the FDA. Read More

FDA Grants Accelerated Approval to Novartis’ Tafinlar and Mekinist Combination

June 24, 2022
The combination treatment led to overall response rates of up to 80 percent. Read More

FDA Expands Approval to Merck’s Vaxneuvance Vaccine in Children From Six Weeks to 17 Years Old

June 23, 2022
Vaxneuvance was first approved by the FDA in July 2021 for adults age 18 years and older. Read More

FDA Expands AbbVie’s Skyrizi Approval to Include Crohn’s Disease

June 21, 2022
The approval was supported by results from three pivotal studies. Read More

EU Launches Rolling Review of Pfizer’s Updated COVID-19 Vaccine

June 17, 2022
The companies also plan to begin submitting data supporting a variant-adapted vaccine to the FDA in the coming weeks. Read More

FDA Approves Alnylam’s Amvuttra for hATTR Amyloidosis Polyneuropathy

June 15, 2022
The approved indication for Amvuttra requires an injection treatment in patients once every three months. Read More

Canada Approves Amylyx’s ALS Drug Albrioza

June 14, 2022
The conditional approval was based on results of a phase 2 study. Read More

EU Grants Conditional Marketing Authorization to Roche’s Lunsumio for Follicular Lymphoma

June 10, 2022
Lunsumio demonstrated high complete response rates in a phase 1/2 study. Read More

Veru Submits EUA for Treatment of COVID-19 Hospitalized Patients

June 9, 2022
Sabizabulin demonstrated a 55.2 percent reduction in deaths relative to the untreated cohort. Read More
Previous 1 2 3 4 5 6 7 8 9 … 290 291 Next

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing